Multiple myeloma (MM) is a type of blood cancer that typically has no cure. Treatments like medications and stem cell ...

Blood cancers account for about 10 percent of new cancer cases each year. While the cause for most is unknown, research and treatments are improving rapidly.

The Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab-irfc) in combination with bortezomib, lenalidomide and dexamethasone (VRd) for the treatment of patients with newly diagnosed ...

The 21st annual meeting of the International Myeloma Society takes place September 25-28, 2024, in Rio de Janiero, Brazil.

Approval based on positive results from the IMROZ phase 3 study demonstrating Sarclisa in combination with bortezomib, lenalidomide, and dexamethasone (VRd) significantly improved progression-free ...

The FDA has approved Sarclisa (isatuximab) as a first-line therapy for blood cancer multiple myeloma as a combination regimen ...

US FDA approves anti-CD38 therapy, Sarclisa in combo with standard-of-care treatment for adult patients with NDMM who are not eligible for transplant: Paris Tuesday, September 24, ...

ImpriMed Unveils Cancer Treatment Prediction Technology at EHA-SfPM Meeting, Expands AI-Driven Precision Medicine Services ...

Global real-world data support the use of autologous hematopoietic stem cell transplant in patients with newly diagnosed multiple myeloma, according to researchers.

And the agency expanded the approval of bimekizumab (Bimzelx) to include psoriatic arthritis, non-radiographic axial spondyloarthritis, and ankylosing spondylitis, UCB Announced.

Doxorubicin Market Doxorubicin Market Dublin, Sept. 23, 2024 (GLOBE NEWSWIRE) -- The "Doxorubicin Market Size, Share & Trends ...

Barely a week after Bruce Springsteen and the E Street Band delivered an already legendary live set beside the Atlantic Ocean ...